Health
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer
TOKYO & BASKING RIDGE, N.J., June 09, 2025--DESTINY-Endometrial01 Ph. 3 Trial of ENHERTU Initiated as 1L Therapy in Patients w/ HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/a8f44475821bf2b226a90330cac2026f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tjh6mPrvJH26p5E1kxnitw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a8f44475821bf2b226a90330cac2026f","width":480,"height":474}},"lazy":false},{"type":"text","content":"TOKYO & BASKING RIDGE, N.J., June 09, 2025--(BUSINESS WIRE)--The first patient has been dosed in the DESTINY-Endometrial01 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in combination with rilvegostomig or pembrolizumab versus platinum-based chemotherapy (carboplatin and paclitaxel) in combination with pembrolizumab as a first-line therapy in patients with HER2 expressing (IHC 3+/ 2+), mismatch repair proficient (pMMR) primary advanced or recurrent endometrial cancer. DESTINY-Endometrial01 will be conducted in collaboration with The GOG Foundation, Inc. (GOG-F) and the European Network of Gynecological Oncological Trial (ENGOT).","length":653,"tagName":"p"},{"type":"text","content":"ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN).","length":229,"tagName":"p"},{"type":"text","content":"Endometrial cancer that is recurrent or diagnosed in advanced stages has a median overall survival of up to 30 months.1 While there have been recent treatment advances, there is still a need to further improve outcomes for patients. HER2 expression (IHC 3+/2+) is associated with aggressive disease and is present in 18% to 56% of endometrial cancers.2,3,4,5,6 There currently are no HER2 directed medicines approved in the first-line endometrial cancer setting.","length":462,"tagName":"p"},{"type":"text","content":""Following the positive results in the endometrial cancer cohort of DESTINY-PanTumor02, which contributed to a tumor agnostic approval for previously treated patients with HER2 positive metastatic tumors in several regions, we are initiating this first phase 3 trial of ENHERTU in the first-line setting of advanced endometrial cancer," said ...